Article Listing - New Insights Into Alcohol Abuse
AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease
17 May 2013
US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext: GLPG) on their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase II program in Crohn's disease, which is designed to facilitate rapid progression into Phase III.
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
17 May 2013
French drug major Sanofi (Euronext: SAN) and NYSE: SNY) this morning (May 17) revealed that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups.
Neovacs moving forward in rheumatoid arthritis, say analysts
17 May 2013
French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead product TNFalpha-Kinoid in rheumatoid arthritis (RA). The strategy is designed to maintain momentum of the programme while it seeks a partner.
Infectious disease treatments market driven by growth in middle-income to low-income countries
17 May 2013
The infectious disease treatments market increased at a compound annual growth rate (CAGR) of 6.9% between 2008 and 2012, reaching a value of around $19 billion at the end of 2012, according to a new report added to the offering of Companiesandmarkets.com.
Bristol-Myers' data on Yervoy and nivolumab causes a stir
17 May 2013
Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting by US drug major Bristol-Myers Squibb (NYSE: BMY), notably extended follow-up from a Phase nivolumab study, results from Phase I nivolumab and Yervoy (ipilimumab; which was approved as a treatment for melanoma in 2011) combination study, and five-year survival data from four Phase II Yervoy studies, caused a great deal of excitement in the investment community.
Bayer to strengthen consumer business with Steigerwald acquisition
17 May 2013
Germany's Bayer (BAYN: DE) has signed an agreement to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, based in Darmstadt, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. Financial terms of the accord were not disclosed.
RuiYi and Genor BioPharma collaborate on development in China of RYI-008
17 May 2013
USA and China-based RuiYi says it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-Interleukin-6 monoclonal antibody with a unique pharmacologic profile that has the potential to define a new paradigm in the treatment of autoimmune diseases and cancer.
Merck KGaA ups commitment to MS Ventures to 100 million euros
16 May 2013
Germany's Merck KGaA says that it will increase its commitment to its strategic corporate venture capital fund MS Ventures to 100 million euros ($130 million). MS Ventures was originally established in March 2009 with a 40 million euros commitment to invest in emerging biotechnology companies.
Vifor gets certain rights to Helsinn's netupitant-palonosetron
16 May 2013
Privately-held Helsinn Healthcare and fellow Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination (NEPA), a Helsinn product currently in the development stage for the treatment of chemotherapy-induced nausea and vomiting (CINV).
Improved voluntary harmonization procedure delivers significant benefits for multinational clinical trials in Europe
16 May 2013
The new Voluntary Harmonization Procedure (VHP), a voluntary procedure agreed by the Clinical Trials Facilitation Group (CTFG), a working group of the EU Heads of Medicines Agencies, provides a major breakthrough in getting a harmonized regulatory decision on a clinical trial to be performed in more than one European Union member state.
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
